查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015198

肽類藥物市場：按產品類型、合成技術、給藥途徑、應用和最終用戶分類－2026-2032年全球市場預測

Peptide Therapeutics Market by Product Type, Synthesis Technique, Route Of Administration, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胜肽類藥物市場價值將達到 1,177.7 億美元，到 2026 年將成長至 1,287 億美元，到 2032 年將達到 2,462.8 億美元，複合年成長率為 11.11%。

主要市場統計數據
基準年 2025 1177.7億美元
預計年份：2026年 1287億美元
預測年份 2032 2462.8億美元
複合年成長率 (%) 11.11%

肽類藥物策略導論：科學進展概述、轉化研究要素及相關人員在臨床開發中的影響

胜肽類療法已從最初的小眾實驗室研究發展成為連接小分子藥物和重磅生物製藥的關鍵治療方法，重塑了藥物發現和臨床診療路徑。過去十年間，胜肽設計、穩定性工程和標靶遞送方面的迭代進步，拓展了肽類療法在代謝紊亂、感染疾病、心血管疾病和腫瘤等多種適應症的應用。本導論分析將胜肽類療法置於生物製藥創新的大背景下，重點在於那些揭示新作用機制和臨床效用價值的轉化里程碑。

電腦輔助設計、藥物傳輸技術的創新以及協作平台策略如何從根本上重塑胜肽類藥物開發的優先事項和流程。

現代胜肽療法的格局正受到多項變革性轉變的重塑，這些轉變正在全面調整研究重點和商業策略。首先，電腦輔助胜肽設計和人工智慧驅動的序列最佳化正在縮短迭代設計週期，並允許優先篩選具有更佳靶點結合和藥物動力學特徵的候選物質。其次，製劑和遞送技術的突破，包括穩定化學和新型賦形劑系統，正在擴大口服和長效腸外給藥胜肽的可行性，提高病患依從性，並為門診給藥開闢新的可能性。

2025 年美國關稅情勢對胜肽供應鏈、籌資策略和臨床生產的連續性的影響。

美國近期實施的關稅調整（將於2025年生效）為胜肽類供應鏈和生產策略帶來了新的複雜性。其累積影響不僅限於直接成本考量，還波及採購決策、採購週期以及生產和品管活動的地理位置。依賴跨國原料採購、專業合成服務或契約製造關係的企業，必須重新評估其供應商體系和庫存策略，以維持臨床和商業生產的連續性。

詳細的細分分析表明，產品類型、合成方法、給藥途徑、治療用途和最終用戶如何形成不同的發展路徑。

基於細分市場的洞察揭示了治療方法和技術選擇如何影響胜肽類藥物的研發重點和商業性定位。根據產品類型，研發人員將其產品組合細分為抗菌肽、細胞滲透性肽、肽激素和胜肽類疫苗，每種產品都有獨特的標靶檢驗、安全性和監管方面的考量。抗菌肽需要進行嚴格的抗藥性分析和製劑開發，以實現局部或全身給藥；而細胞滲透性肽則需要證明其能夠被細胞內吸收並具有良好的載藥相容性。肽激素和肽類疫苗繼續利用現有的監管途徑，但受益於穩定性提升和遞送方案的改進，從而拓展了門診給藥的選擇範圍。

全球各地不同的管理體制、生產實力和臨床重點如何為肽類藥物開發公司帶來獨特的策略挑戰？

肽類療法的區域發展趨勢反映了各主要地區在法規結構、臨床重點、生產生態系統和投資流向方面的差異。在美洲，活躍的創業投資活動、完善的臨床試驗網路和成熟的生物技術中心持續推動早期創新。同時，監管機構優先考慮高需求適應症的快速核准途徑，並就複雜的生物製藥進行結構化對話。因此，該地區的申辦者通常優先進行快速概念驗證臨床試驗，並與專業的合約研發機構（CDMO）建立策略合作夥伴關係，以將研究成果轉化為臨床適用的候選藥物。

競爭分析重點介紹了專業生物技術公司、平台創新者和 CDMO 如何塑造胜肽類藥物領域的轉化和商業性成功。

肽類藥物領域的競爭動態呈現出多層次的生態系統特徵，該生態系統由專注於藥物研發的生物技術企業、平台技術提供者以及擁有商業化專長的大型製藥合作夥伴組成。早期公司通常專注於特定適應症或新型遞送方式，利用其專業知識並與學術機構合作來檢驗作用機制。同時，平台技術公司則投資於模組化化學、穩定化技術和偶聯策略，以透過授權和合作拓展其治療應用範圍。

相關人員現在應該實施切實可行的跨領域舉措，以降低研發管線風險，增強供應韌性，並加速胜肽類創新技術的臨床應用。

行業領導者必須採取前瞻性和綜合性的策略，將肽療法的科學進步轉化為永續的臨床和商業性成果。首先，將藥物研發的優先事項與下游生產的實際情況結合至關重要。團隊應在設計週期的早期階段就納入可生產性標準和監管方面的考量，以減少技術缺陷並加快臨床試驗的準備。建立一個涵蓋藥物研發人員、製程開發專家、監管人員和商業負責人的跨職能管治結構，可以確保在創新和可執行性之間做出平衡的決策。

一種透明且可重複的調查方法，結合專家訪談、文獻整合和基於情境的分析，為胜肽開發中的策略決策提供支援。

本分析整合了來自一手和二手研究的發現，旨在對胜肽類藥物的現狀進行嚴謹的闡述。一手研究包括對產業專家、生產和監管專家以及臨床研究人員進行結構化訪談，以了解實務經驗和策略重點。二手資訊來源包括同行評審文獻、監管指導文件以及公開的研發項目信息，檢驗科學趨勢和監管先例。整個分析過程中均採用了資料三角驗證法，以檢驗不同的觀點，並確保結論是基於多方面的證據。

結論是，技術、法規和營運策略的整合決定了哪些胜肽類開發專案能夠取得臨床和商業性的成功。

胜肽類療法正處於一個轉折點，這得益於設計、合成和遞送技術的進步，以及生產和分銷實際環境的變化。這些因素共同拓展了胜肽類的治療範圍，並迫使企業在平台開發、法規遵循和供應鏈韌性方面提升自身能力。在此環境下，成功取決於能否將科學創新與切實可行的實施策略結合，從而預見營運限制和相關人員的期望。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：胜肽類治療市場：依產品類型分類

  • 抗菌胜肽
  • 細胞滲透性肽
  • 肽激素
  • 胜肽疫苗

第9章 胜肽類治療藥物市場（依合成方法）

  • 重組胜肽
  • 合成胜肽

第10章：胜肽類治療藥物市場：依給藥途徑分類

  • 吸入
  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服
    • 膠囊
    • 液體
    • 藥片
  • 外用
  • 經皮

第11章 胜肽類治療市場：依應用領域分類

  • 心血管疾病
    • 心臟衰竭
    • 高血壓
  • 感染疾病
    • 肝炎
    • HIV
    • 流感
  • 代謝性疾病
    • 糖尿病
    • 肥胖
  • 腫瘤學
    • 乳癌
    • 肺癌
    • 惡性黑色素瘤

第12章 胜肽類治療藥物市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構

第13章 胜肽類治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 胜肽類治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 胜肽類治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國胜肽類治療藥物市場

第17章：中國胜肽類治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Bachem Holding AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Ipsen SA
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S
Product Code: MRR-030EE4851583

The Peptide Therapeutics Market was valued at USD 117.77 billion in 2025 and is projected to grow to USD 128.70 billion in 2026, with a CAGR of 11.11%, reaching USD 246.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 117.77 billion
Estimated Year [2026] USD 128.70 billion
Forecast Year [2032] USD 246.28 billion
CAGR (%) 11.11%

A strategic primer on peptide therapeutics that frames scientific advances, translational enablers, and stakeholder implications for clinical development

Peptide therapeutics have evolved from niche laboratory curiosities into a pivotal modality bridging small molecules and large biologics, reshaping drug discovery and clinical care pathways. Over the past decade, iterative advances in peptide design, stability engineering, and targeted delivery have expanded the therapeutic scope of peptides across metabolic, infectious, cardiovascular, and oncologic indications. This introductory analysis situates peptide therapeutics within the larger biopharmaceutical innovation landscape, emphasizing translational milestones that have unlocked new mechanisms of action and clinical utility.

Translating peptide science into viable therapies has required harmonized progress across chemistry, synthesis techniques, and formulation science. Improvements in solid-phase synthesis, recombinant production, and novel conjugation strategies have increased the chemical diversity and manufacturability of peptide assets. At the same time, regulatory agencies have refined their frameworks for assessing peptide-related quality attributes, which has reduced ambiguity in development pathways and supported more predictable interactions between sponsors and regulators. Consequently, research institutions, small biotechs, and established pharmaceutical companies are increasingly aligning resources to accelerate peptide pipelines.

Looking ahead, the introduction of next-generation stabilization chemistries, enhanced delivery platforms, and computational design tools will continue to lower barriers to clinical translation. As a result, stakeholders must adopt integrated strategies that coordinate discovery, development, and manufacturing to capitalize on the modality's unique therapeutic potential while managing complexity across regulatory, supply chain, and payer landscapes.

How computational design, delivery innovations, and collaborative platform strategies are fundamentally reshaping priorities and pathways in peptide drug development

The contemporary peptide therapeutics landscape is being remade by several transformative shifts that collectively recalibrate research priorities and commercial strategies. First, computational peptide design and AI-enabled sequence optimization have shortened iterative design cycles, enabling teams to prioritize candidates with improved target engagement and pharmacokinetic profiles. Second, breakthroughs in formulation and delivery, including stabilization chemistries and novel excipient systems, have expanded the feasibility of oral and long-acting parenteral peptides, broadening potential patient adherence and outpatient administration.

In parallel, evolving clinical needs are driving diversification of peptide applications. Antimicrobial peptides are being revisited as tools against antimicrobial resistance, while cell penetrating peptides are opening new avenues for intracellular targeting and oligonucleotide delivery. Peptide vaccines are benefiting from improved antigen design and adjuvant systems, positioning them as complementary or alternative approaches to traditional vaccine platforms. These scientific advances are amplified by more fluid collaboration models that bring together academic labs, specialized contract developers, and integrated biopharma teams, thereby accelerating translational momentum.

Concurrently, manufacturing innovations are reshaping production economics and scalability. Recombinant production methods and sequence-optimized synthetic approaches are reducing technical constraints for larger peptides and peptide conjugates. As a result, strategic priorities among developers are shifting from single-asset optimization toward platform capabilities that can support modular pipeline expansion and faster commercialization pathways. Together, these shifts are creating a more dynamic, multidisciplinary ecosystem for peptide therapeutics.

Operational implications of the 2025 United States tariff landscape on peptide supply chains, procurement strategies, and clinical manufacturing continuity

Recent tariff adjustments implemented by the United States in 2025 have introduced a new layer of complexity for peptide supply chains and manufacturing strategies. The cumulative impact extends beyond direct cost implications to influence sourcing decisions, procurement cycles, and geographic allocation of production and quality control activities. Organizations that rely on cross-border raw material procurement, specialized synthesis services, or contract manufacturing relationships have had to re-evaluate their supplier matrices and inventory policies to preserve continuity of clinical and commercial production.

Moreover, the tariff environment has accelerated strategic conversations about localization versus diversification. Some entities are exploring nearer-shoring of critical peptide synthesis and fill/finish capabilities to mitigate exposure to import levies and border-related delays, while others are negotiating longer-term contracts with international suppliers to lock in price stability and access. Legal and compliance teams are simultaneously examining classification codes and supply-chain traceability measures to ensure accurate tariff treatment and to identify potential exemptions where applicable. These operational adjustments have also prompted sponsors to reassess timelines for clinical trial material manufacturing and to integrate tariff risk into procurement governance.

In response, industry participants are adopting mixed mitigation strategies that include dual-sourcing arrangements, onshore capacity investments, and enhanced inventory resilience. As a consequence, development teams are increasingly incorporating tariff scenarios into program risk registers and contingency planning, thereby aligning financial planning with operational realities and preserving patient access commitments while navigating a more fragmented trade landscape.

In-depth segmentation insights showing how product types, synthesis methods, administration routes, therapeutic applications, and end users drive divergent development pathways

Segmentation-driven insights reveal how therapeutic and technical choices influence development priorities and commercial positioning across peptide modalities. Based on product type, developers are differentiating portfolios across antimicrobial peptides, cell-penetrating peptides, peptide hormones, and peptide vaccines, each presenting distinct target validation, safety, and regulatory considerations. Antimicrobial peptides require rigorous resistance profiling and formulation approaches for local or systemic delivery, whereas cell-penetrating peptides demand proof of cellular uptake and payload compatibility. Peptide hormones and peptide vaccines continue to leverage established regulatory pathways but benefit from enhanced stability and delivery solutions that expand outpatient administration options.

Based on synthesis technique, the strategic calculus shifts between recombinant peptides and synthetic peptides, with recombinant methods offering scalability and post-translational mimicry while synthetic approaches provide sequence flexibility and chemical modification opportunities. Development teams must therefore align lead optimization strategies with the chosen production paradigm to ensure downstream manufacturability. Based on route of administration, modality decisions are informed by clinical context: inhalation, injectable, oral, topical, and transdermal pathways each carry different formulation constraints and patient adherence implications. Injectable formats-further delineated into intramuscular, intravenous, and subcutaneous-remain dominant for many biologically active peptides, while oral forms-further categorized into capsule, liquid, and tablet-are becoming feasible for select stabilized sequences.

Based on application, therapeutic focus areas such as cardiovascular diseases, infectious diseases, metabolic disorders, and oncology require tailored translational evidence. Cardiovascular subdomains like heart failure and hypertension pose unique safety and dosing challenges, infectious disease workstreams such as hepatitis, HIV, and influenza emphasize antiviral potency and resistance surveillance, metabolic disorder programs for diabetes and obesity prioritize chronic dosing paradigms and adherence, and oncology indications including breast cancer, lung cancer, and melanoma spotlight targeted delivery and combination strategies. Finally, based on end user, clinics, hospitals, and research institutes exert distinct procurement and implementation pressures that shape positioning, pricing strategies, and evidence generation plans for peptide-based interventions.

How varied regulatory regimes, manufacturing strengths, and clinical priorities across global regions shape distinct strategic imperatives for peptide developers

Regional dynamics in peptide therapeutics reflect differences in regulatory frameworks, clinical priorities, manufacturing ecosystems, and investment flows across major geographies. In the Americas, strong venture capital activity, advanced clinical trial networks, and established biotech hubs continue to fuel early-stage innovation, while regulatory agencies emphasize expedited pathways for high-need indications and structured dialogues for complex biologics. Consequently, sponsors in this region often prioritize rapid clinical proof-of-concept studies and strategic alliances with specialized contract development organizations to translate discoveries into clinic-ready candidates.

Europe, the Middle East & Africa presents a mosaic of regulatory and reimbursement environments with deep academic research capabilities and specialized manufacturing clusters. Cross-border collaborations and consortium-based translational programs are common, supporting peptide vaccine development and infectious disease initiatives where regional public health priorities drive funding and trial recruitment. Here, navigating heterogeneous regulatory expectations and leveraging pan-regional trial networks are key to advancing multi-center programs.

Asia-Pacific combines robust manufacturing scale, rising domestic biopharma talent, and growing healthcare demand, making it a focal point for production capacity and late-stage development activities. Governments across the region continue to invest in biotech infrastructure and manufacturing capability expansion, prompting some organizations to consider Asia-Pacific as a strategic production partner for peptide APIs and formulations. Across all regions, alignment of clinical strategies with local healthcare delivery models and payer expectations remains essential for successful adoption and sustained commercialization.

Analysis of competitive dynamics highlighting how specialized biotechs, platform innovators, and CDMOs shape translational and commercial success in peptide therapeutics

Competitive dynamics in the peptide therapeutics sector are characterized by a layered ecosystem of discovery-focused biotech ventures, platform technology providers, and larger pharmaceutical partners that bring commercialization expertise. Early-stage companies frequently concentrate on niche indications or novel delivery concepts, leveraging specialized scientific expertise and academic collaborations to validate mechanisms of action. At the same time, platform technology firms are investing in modular chemistries, stabilization techniques, and conjugation strategies that can be licensed or partnered to broaden therapeutic reach.

Contract development and manufacturing organizations play a critical role in enabling scale-up and regulatory compliance, offering capabilities that range from research-grade peptide synthesis to GMP production and fill-finish services. These service providers are increasingly differentiating themselves through quality systems, regulatory support offerings, and flexible manufacturing models that accommodate both small-batch clinical material needs and larger commercial volumes. Larger pharmaceutical companies and strategic investors continue to shape the landscape through targeted collaborations, licensing deals, and integration of peptide assets into broader therapeutic portfolios.

Together, these actors create an environment where strategic alignment, intellectual property strategy, and operational excellence determine competitive positioning. Companies that combine robust translational science with clear manufacturing pathways and proactive regulatory engagement are better positioned to move candidates efficiently through development and into clinical practice.

Practical, cross-functional actions that stakeholders should implement now to de-risk pipelines, strengthen supply resiliency, and accelerate clinical translation of peptide innovations

Industry leaders must adopt proactive, integrated strategies to convert scientific advances in peptide therapeutics into durable clinical and commercial outcomes. First, aligning discovery priorities with downstream manufacturing realities is essential; teams should embed manufacturability criteria and regulatory considerations early in the design cycle to reduce technical attrition and accelerate clinical readiness. Establishing cross-functional governance that includes discovery scientists, process development specialists, regulatory leads, and commercial strategists will ensure decisions balance innovation with practical execution.

Second, diversifying supply chains and developing contingency plans for trade and tariff volatility will protect clinical program timelines. Strategic options include dual sourcing of critical raw materials, selective onshoring or nearer-shoring of key production steps, and forging long-term partnerships with trusted contract manufacturers. These measures, combined with enhanced inventory and quality traceability systems, will reduce operational risk and support timely product availability.

Third, invest in platform capabilities that increase program throughput and adaptability. This includes adopting modular synthesis platforms, leveraging in silico design tools to prioritize candidates, and developing flexible formulation approaches that can be adapted across routes of administration. Finally, cultivate collaborative partnerships with academic centers, health systems, and payer stakeholders to co-develop evidence generation plans that demonstrate real-world value and facilitate adoption. Executed together, these actions will strengthen program resilience and maximize the probability of successful translation and market access.

Transparent and reproducible research methods combining expert interviews, literature synthesis, and scenario-based analysis to support strategic decision-making in peptide development

This analysis synthesizes primary and secondary research inputs to present a rigorous view of the peptide therapeutics landscape. Primary research included structured interviews with industry experts, manufacturing and regulatory specialists, and clinical investigators to capture operational experiences and strategic priorities. Secondary sources encompassed peer-reviewed literature, regulatory guidance documents, and public disclosures of development programs to validate scientific trends and regulatory precedents. Data triangulation was used throughout to reconcile divergent perspectives and to ensure conclusions are grounded in multiple lines of evidence.

Analytical processes prioritized transparency and reproducibility. Key themes were identified through coding of qualitative interview data and cross-checked against documented technological advances and regulatory milestones. Where appropriate, scenario analyses were applied to assess operational implications of external factors such as trade policy changes and supply chain disruptions. Limitations of the methodology are acknowledged: insights reflect the viewpoints of interviewed experts and public information available at the time of research, and they do not substitute for bespoke due diligence tailored to specific corporate circumstances.

Nevertheless, by integrating multidisciplinary inputs and applying a consistent analytical framework, the research offers a robust foundation for strategic decision-making. Stakeholders are encouraged to use the methodology notes and expert appendices included with the full report to interpret findings in the context of their own risk tolerance and operational constraints.

Concluding perspective on how integrated technical, regulatory, and operational strategies will determine which peptide initiatives achieve clinical and commercial success

Peptide therapeutics stand at an inflection point driven by converging advances in design, synthesis, and delivery, alongside shifting operational realities in manufacturing and trade. Collectively, these forces are expanding the therapeutic applicability of peptides and compelling organizations to adopt new capabilities in platform development, regulatory navigation, and supply-chain resilience. In this environment, success will depend on the ability to integrate scientific innovation with pragmatic execution strategies that anticipate operational constraints and stakeholder expectations.

As programs move from discovery to clinic, prioritizing manufacturability, regulatory clarity, and evidence generation will reduce technical and commercial risk. Simultaneously, embracing flexible sourcing strategies and strategic partnerships will mitigate exposure to external shocks such as tariff shifts or supply-chain disruptions. Ultimately, organizations that align technical excellence with strategic foresight will be best positioned to translate peptide science into meaningful patient impact and sustainable business models.

The conclusions presented here are intended to guide executives, R&D leaders, and operational managers as they refine portfolios, plan investments, and pursue collaborations. For teams seeking deeper diagnostic analysis or tailored scenario planning, the full report provides expanded evidence, case studies, and operational playbooks to support implementation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptide Therapeutics Market, by Product Type

  • 8.1. Antimicrobial Peptides
  • 8.2. Cell Penetrating Peptides
  • 8.3. Peptide Hormones
  • 8.4. Peptide Vaccines

9. Peptide Therapeutics Market, by Synthesis Technique

  • 9.1. Recombinant Peptides
  • 9.2. Synthetic Peptides

10. Peptide Therapeutics Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Injectable
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Oral
    • 10.3.1. Capsule
    • 10.3.2. Liquid
    • 10.3.3. Tablet
  • 10.4. Topical
  • 10.5. Transdermal

11. Peptide Therapeutics Market, by Application

  • 11.1. Cardiovascular Diseases
    • 11.1.1. Heart Failure
    • 11.1.2. Hypertension
  • 11.2. Infectious Diseases
    • 11.2.1. Hepatitis
    • 11.2.2. Hiv
    • 11.2.3. Influenza
  • 11.3. Metabolic Disorders
    • 11.3.1. Diabetes
    • 11.3.2. Obesity
  • 11.4. Oncology
    • 11.4.1. Breast Cancer
    • 11.4.2. Lung Cancer
    • 11.4.3. Melanoma

12. Peptide Therapeutics Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Peptide Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Peptide Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Peptide Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Peptide Therapeutics Market

17. China Peptide Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Bachem Holding AG
  • 18.8. Bristol Myers Squibb Company
  • 18.9. Eli Lilly and Company
  • 18.10. GlaxoSmithKline plc
  • 18.11. Ipsen S.A.
  • 18.12. Merck & Co., Inc.
  • 18.13. Novartis AG
  • 18.14. Novo Nordisk A/S
  • 18.15. Pfizer Inc.
  • 18.16. Sanofi S.A.
  • 18.17. Takeda Pharmaceutical Company Limited
  • 18.18. Teva Pharmaceutical Industries Ltd.
  • 18.19. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 228. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 231. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 234. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 264. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 267. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 269. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 270. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 276. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 279. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 281. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 282. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)